Compare ESEA & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESEA | DNA |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | Greece | United States |
| Employees | N/A | 485 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 455.8M |
| IPO Year | 2005 | N/A |
| Metric | ESEA | DNA |
|---|---|---|
| Price | $66.11 | $9.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $8.50 |
| AVG Volume (30 Days) | 73.0K | ★ 1.2M |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.60 | $5.37 |
| 52 Week High | $78.76 | $17.58 |
| Indicator | ESEA | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 59.00 |
| Support Level | $66.29 | $7.59 |
| Resistance Level | $71.86 | $10.27 |
| Average True Range (ATR) | 2.69 | 0.74 |
| MACD | 0.39 | 0.01 |
| Stochastic Oscillator | 53.44 | 53.10 |
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.